Hugo Arasanz

List of Publications by Year
in descending order

25 papers	1,360 citations	567144 15 h-index	552653 26 g-index
31 all docs	31 docs citations	31 times ranked	2124 citing authors

#	Article	IF	Citations
1	PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity. Cell Reports, 2017, 20, 1818-1829.	2.9	220
2	PD1 signal transduction pathways in T cells. Oncotarget, 2017, 8, 51936-51945.	0.8	191
3	The intracellular signalosome of PD-L1 in cancer cells. Signal Transduction and Targeted Therapy, 2018, 3, 26.	7.1	174
4	Functional systemic CD4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy. EMBO Molecular Medicine, 2019, 11, e10293.	3.3	145
5	Understanding LAG-3 Signaling. International Journal of Molecular Sciences, 2021, 22, 5282.	1.8	78
6	Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics. Cancers, 2020, 12, 344.	1.7	60
7	PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer. International Journal of Molecular Sciences, 2019, 20, 1631.	1.8	59
8	A core of kinase-regulated interactomes defines the neoplastic MDSC lineage. Oncotarget, 2015, 6, 27160-27175.	0.8	51
9	Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy. Annals of Translational Medicine, 2017, 5, 385-385.	0.7	50
10	Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?. Frontiers in Pharmacology, 2020, 11, 441.	1.6	48
11	Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy. Frontiers in Immunology, 2020, 11, 586907.	2.2	40
12	Clinical landscape of LAG-3-targeted therapy. Immuno-Oncology Technology, 2022, 14, 100079.	0.2	37
13	Myeloid-Derived Suppressor Cells in the Tumor Microenvironment: Current Knowledge and Future Perspectives. Archivum Immunologiae Et Therapiae Experimentalis, 2018, 66, 113-123.	1.0	36
14	Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies. International Journal of Molecular Sciences, 2020, 21, 2411.	1.8	28
15	Characterization of Macrophage Endogenous S-Nitrosoproteome Using a Cysteine-Specific Phosphonate Adaptable Tag in Combination with TiO_2 Chromatography. Journal of Proteome Research, 2018, 17, 1172-1182.	1.8	21
16	Systemic CD4 immunity: A powerful clinical biomarker for PD‐L1/PD‐1 immunotherapy. EMBO Molecular Medicine, 2020, 12, e12706.	3.3	19
17	Hyperprogressive Disease: Main Features and Key Controversies. International Journal of Molecular Sciences, 2021, 22, 3736.	1.8	18
18	PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy. International Journal of Molecular Sciences, 2020, 21, 5918.	1.8	15

#	Article	IF	Citations
19	Profound Reprogramming towards Stemness in Pancreatic Cancer Cells as Adaptation to AKT Inhibition. Cancers, 2020, 12, 2181.	1.7	9
20	The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity. British Journal of Cancer, 2022, 126, 1168-1177.	2.9	9
21	CAR-T Cells for the Treatment of Lung Cancer. Life, 2022, 12, 561.	1.1	8
22	Immunotherapy in malignant melanoma: recent approaches and new perspectives. Melanoma Management, 2017, 4, 39-48.	0.1	7
23	A Proteomic Atlas of Lineage and Cancer-Polarized Expression Modules in Myeloid Cells Modeling Immunosuppressive Tumor-Infiltrating Subsets. Journal of Personalized Medicine, 2021, 11, 542.	1.1	6
24	Novel immunotherapies for the treatment of melanoma. Immunotherapy, 2016, 8, 613-632.	1.0	5
25	Systemic immunological biomarkers of clinical responses in immune checkpoint blockade therapies. Lung Cancer Management, 2018, 7, LMT07.	1.5	1